title: Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
abstract: BACKGROUND
  The complex pharmacological profile of the antiparkinsonian drug budipine influences neurotransmission beyond the dopaminergic system. Previous studies have demonstrated the therapeutic efficacy of budipine on motor symptoms in insufficiently treated patients with Parkinson disease.
  
  
  OBJECTIVE
  To demonstrate the efficacy of 20 mg of budipine, 3 times daily, in addition to a stable, prior, optimum-titrated dopaminergic substitution consisting of a combination of levodopa and a dopa decarboxylase inhibitor, bromocriptine mesylate, and optional selegiline hydrochloride in 99 patients with idiopathic Parkinson disease in a multicenter, double-blind, placebo-controlled trial.
  
  
  RESULTS
  Budipine significantly (P<.001) decreased the Columbia University Rating Scale sum score (median, 15.0; 95% confidence interval, 11.3-17.0) compared with placebo (median, 4.3; 95% confidence interval, 3.0-7.5) at study end point. Budipine reduced Columbia University Rating Scale subscores for tremor, rigidity, and akinesia.
  
  
  CONCLUSIONS
  The additional application of budipine provides further therapeutic benefit in subjects with Parkinson disease receiving a stable, prior, optimum-titrated dopaminergic drug regimen because of the hypothetical positive impact of budipine on altered nondopaminergic neurotransmission in patients with Parkinson disease.
authors.affiliation: Department of Neurology, Ruhr University of Bochum, Gudrunstrass 56, 44791 Bochum, Germany. Horst.Przuntek@ruhr-uni-bochum.de
authors.forename: Horst
authors.initials: H
authors.lastname: Przuntek
authors.forename: Stefan
authors.initials: S
authors.lastname: Bittkau
authors.forename: Harald
authors.initials: H
authors.lastname: Bliesath
authors.forename: Ulrich
authors.initials: U
authors.lastname: Büttner
authors.forename: Gerd
authors.initials: G
authors.lastname: Fuchs
authors.forename: Joachim
authors.initials: J
authors.lastname: Glass
authors.forename: Harald
authors.initials: H
authors.lastname: Haller
authors.forename: Thomas
authors.initials: T
authors.lastname: Klockgether
authors.forename: Peter
authors.initials: P
authors.lastname: Kraus
authors.forename: Lutz
authors.initials: L
authors.lastname: Lachenmayer
authors.forename: Dieter
authors.initials: D
authors.lastname: Müller
authors.forename: Thomas
authors.initials: T
authors.lastname: Müller
authors.forename: Bernhard
authors.initials: B
authors.lastname: Rathay
authors.forename: Jörg
authors.initials: J
authors.lastname: Sgonina
authors.forename: Volker
authors.initials: V
authors.lastname: Steinijans
authors.forename: Elemer
authors.initials: E
authors.lastname: Teshmar
authors.forename: Gudrun
authors.initials: G
authors.lastname: Ulm
authors.forename: Dieter
authors.initials: D
authors.lastname: Volc
mesh_terms: D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D010880:Piperidines; D001971:Bromocriptine; D007980:Levodopa; C026710:budipine